A multimodal diagnostic matrix for emergency gynaecological triage: retrospective correlation of patient age, clinical features, serum tumour markers and O-RADS risk stratification in adnexal mass management

Anjali Gitte; Reena Wani; Pooja Champanerkar; Vaishnavi Dange

doi:10.18203/2320-1770.ijrcog20263423

Authors

Anjali Gitte Department of Obstetrics and Gynaecology, HBTMC and Dr. R. N. Cooper Hospital, Mumbai, Maharashtra, India
Reena Wani Department of Obstetrics and Gynaecology, HBTMC and Dr. R. N. Cooper Hospital, Mumbai, Maharashtra, India
Pooja Champanerkar Department of Obstetrics and Gynaecology, HBTMC and Dr. R. N. Cooper Hospital, Mumbai, Maharashtra, India
Vaishnavi Dange Department of Obstetrics and Gynaecology, HBTMC and Dr. R. N. Cooper Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20263423

Keywords:

Adnexal mass, O-RADS ultrasound, O-RADS MRI, Tumour markers, CA-125, HE4, ROMA index, Ectopic pregnancy

Abstract

Background: Evaluating adnexal masses in the emergency setting requires rapid clinical decision-making to differentiate surgical emergencies from benign or self-limiting conditions. While ultrasound using the ovarian-adnexal reporting and data system (O-RADS) framework serves as the primary diagnostic tool, acute pelvic infections and inflammatory masses frequently display acoustic features mimicking malignancy. This study evaluates the diagnostic performance of an integrated matrix combining patient demographics, clinical presentation, serum tumour markers [CA-125, human epididymis protein 4 (HE4), and the risk of ovarian malignancy algorithm (ROMA) index], and multimodal O-RADS imaging (US and MRI) in guiding clinical triage.

Methods: A retrospective observational study was conducted analysing 200 women admitted with adnexal lesions between July 2025 and June 2026. Clinical characteristics, initial ultrasound findings, selective serum biomarkers, and secondary O-RADS MRI findings were correlated with final histopathological diagnoses or documented clinical resolution. Statistical analysis utilized Chi-square tests, student's t tests, and receiver operating characteristic (ROC) curves with 95% confidence intervals (CI).

Results: The cohort comprised ectopic gestation (n=72, 36.0%), acute inflammatory mass/ tubo-ovarian abscesses (TOA) (n=52, 26.0%), endometrioma (n=32, 16.0%), simple/benign cysts (n=28, 14.0%), and ovarian malignancy (n=16, 8.0%). Marker evaluation was selectively performed in 128 non-ectopic cases and omitted in ectopic pregnancies (n=72). Initial O-RADS ultrasound alone demonstrated high sensitivity (93.8%) but lower specificity (71.9%) due to complex inflammatory collections mimicking ovarian cancer. Incorporating HE4, ROMA index, and secondary O-RADS MRI significantly improved diagnostic specificity to 95.1% (95% CI: 90.2%-98.0%) and positive predictive value (PPV) to 92.6% (p<0.001), accurately reclassifying TOA and endometriomas as benign and preventing unnecessary emergency surgery.

Conclusions: Integrating clinical parameters and selective serum biomarkers with multimodal O-RADS imaging provides a robust diagnostic matrix in emergency OBGY admissions, facilitating conservative or elective management for benign conditions while expediting oncological referral pathways.

References

Timmerman D, Van Calster B, Testa A, Guerriero S, Fischerova D, Lissoni AA, et al. Predicting the risk of malignancy in adnexal masses based on the International Ovarian Tumour Analysis (IOTA) terminology. BMC Cancer. 2016;16:205.

Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal masses: comparison of five expert ultrasound-based strategies in a prospective multicenter study. Ultrasound Obstet Gynecol. 2014;44(1):41-7.

Strachowski LM, Jha P, Bapat MB, Benacerraf BR, Brown DL, Coleman BG, et al. O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee. Radiology. 2023;308(3):e230685.

Vara J, Pagliuca M, Springer S, Lucena U, Bermejo C, Garcia-Ruiz R, et al. O-RADS Classification for Ultrasound Assessment of Adnexal Masses: Agreement between IOTA Lexicon and ADNEX Model for Assigning Risk Group. Diagnostics (Basel). 2023;13(4):673.

Andreotti RF, Timmerman D, Strachowski LM, Froychana W, Benacerraf BR, Brown DL, et al. O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR O-RADS Committee. Radiology. 2020;294(1):168-85.

Piovano E, Cavallero C, Buca D, Fuso L, Triunfo S, Scambia G, et al. The role of ultrasound and tumor markers in the triage of adnexal masses. Int J Gynecol Cancer. 2022;32(3):301-9.

Guo Y, Wang Y, Wang J, Zhang X, Zhang Y. Diagnostic performance of O-RADS ultrasound and O-RADS MRI in adnexal masses: A systematic review and meta-analysis. Eur Radiol. 2023;33(2):1201-12.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, Risk of Ovarian Malignancy Algorithm (ROMA), and Risk of Malignancy Index (RMI) for the classification of adnexal masses. Clinics (Sao Paulo). 2012;67(5):437-41.

Bast RC Jr, Badgwell D, Lu Z, Lu KH, Levin MG, Dai J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(3):274-81.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142(2):99-105.

Dochez V, Caillon H, Vaucel E, Pasquier J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Lydolph MC, Aarenstrup Karlsen N, et al. Evaluation of HE4, CA125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127(2):379-83.

Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay (Epithelial Ovarian Cancer MDM) and CA-125 alone for the prediction of ovarian malignancy. Gynecol Oncol. 2010;118(3):280-5.

Sadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, et al. O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee. Radiology. 2022;303(1):35-47.

Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS, Stojanovic S, et al. O-RADS MRI score for risk stratification of sonographically indeterminate adnexal masses. JAMA Netw Open. 2020;3(1):e1919896.

Basha MAA, Refaat R, Ibrahim SA, Madkour NM, AlAzzazy EH, Zoair AM, et al. Diagnostic efficacy of O-RADS US and MRI in characterization of adnexal masses. Eur Radiol. 2021;31(9):6980-91.

Westwood M, Ramaekers B, Lang S, Armstrong N, Noake C, de Kock S, et al. Risk of ovarian malignancy algorithm (ROMA) and Human Epididymis Protein 4 (HE4) for the diagnosis of ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2019;23(14):1-320.